FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004245816> ?p ?o ?g. }

• W3004245816 endingPage "497" @default.
• W3004245816 startingPage "495" @default.
• W3004245816 abstract "Lung cancer is the most common primary cancer of the lung and is responsible for the ever increasing number of cancer-related deaths worldwide.1 Especially in China, the burden of lung cancer has been rising rapidly due to its large and growing population.2 Histologically, approximately 85% of lung cancers are non-small-cell lung cancer (NSCLC).3 Molecular targeted therapy has been shown to dramatically improve the quality of life and survival outcomes of NSCLC patients. One of the most important targeted drugs in NSCLC has been the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). In 2009, the IPASS study demonstrated that metastatic NSCLC patients with sensitizing EGFR mutations who received gefitinib treatment had better outcomes than patients with standard chemotherapy.4 Subsequent phase III clinical trials of the first- and second-generation EGFR-TKIs, such as gefitinib, erlotinib, afatinib, dacomitinib, have also confirmed that these drugs could effectively improve the objective response rate and prolong progression-free survival.4-8 Likewise, the ongoing ACTIVE study has also preliminary demonstrated that apatinib plus gefitinib could be used as first-line treatment for patients with EGFR-mutant advanced NSCLC.9 Osimertinib is a third-generation EGFR-TKI that can selectively inhibit sensitizing mutations and Thr790Met mutation.10 At present, it is approved for the first-line treatment of patients with metastatic NSCLC harboring EGFR Thr790Met mutations and specific Leu858Arg mutation.11, 12 A previous study found that osimertinib possessed greater central nervous system (CNS) activity compared to the first-generation of EGFR-TKIs and standard chemotherapy.12 In NSCLC, approximately 25%–20% of EGFR mutations are rare mutations that consist of a group of highly heterogeneous molecular alterations.13 Several previous studies have shown that NSCLC patients harboring rare EGFR mutations have inconsistent responses to first- or second-generation EGFR-TKIs.14, 15 However, whether third-generation EGFR-TKIs, such as osimertinib, can be used to treat NSCLC patients with rare EGFR mutations is still unknown. In a recent study published in the Journal of Clinical Oncology entitled “Osimertinib for Patients with Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)”,16 the authors provided the first evidence about the efficacy of osimertinib in treating patients with NSCLC harboring rare EGFR mutations. They recruited 37 metastatic or recurrent NSCLC patients from seven institutes in Korea between March 2016 and October 2017. A total of 36 patients were included in the safety and efficacy analyses. They were over 19 years old (median age: 60 years old) and histologically diagnosed as carrying rare EGFR mutations (19 [53%] Gly719Xaa, nine [25%] Leu861Gln, eight [22%] Ser768Ile, and four [11%] others). Among them, 22 (61%) patients received osimertinib treatment as first-line therapy. Their objective response rate was 50% (95% confidence interval [CI]: 33%–67%), median progression-free survival was 8.2 months (95% CI, 5.9–10.5 months) and median duration of response was 11.2 months (95% CI: 7.7–14.7 months). A total of 11 (31%) patients developed rash, nine (25%) pruritus, nine (25%) decreased appetite, eight (22%) diarrhea, and eight (22%) dyspnea. However, all adverse events were manageable. These results demonstrated that osimertinib was effective in the treatment of NSCLC patients with rare EGFR mutations and that the toxicities caused by the treatment were acceptable. Because of the high heterogeneity and low incidence of rare mutations in EGFR, it has been difficult to evaluate the efficacy of EGFR-TKIs in the treatment of NSCLC with rare EGFR mutations. Preliminary studies have observed inconsistent responses with first- or second-generation EGFR-TKIs in NSCLC patients with common and rare EGFR mutations, respectively. Given that third-generation EGFR-TKIs have more advantages than the first- and second-generation EGFR-TKIs, it is therefore necessary to explore the therapeutic effects of the third-generation of EGFR-TKIs in NSCLC patients harboring rare EGFR mutations. Yang et al.17 analyzed the data from the LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 clinical trials and found that afatinib-treated NSCLC patients with some rare EGFR mutations had an objective response rate of 71% and a progression-free survival of 11 months. Only the patients with Thr790Met or exon 20 insertion mutations had an objective response rate of 9%–14% and a progression-free survival of less than three months. Based on these data, the U.S. Food and Drug Administration expanded the indications of afatinib to make it available as a first-line treatment for NSCLC patients with Gly719Xaa, Leu861Gln, Ser768Ile EGFR mutations. The LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6 clinical trials were mainly focused on the therapeutic effect of afatinib in treating NSCLC patients with common EGFR mutations but not for those with rare EGFR mutations. In contrast, the present study 16 focused only on rare EGFR mutations and a subset analysis by rare mutation type was performed. The results indicated that osimertinib had a response rate comparable to other EGFR-TKIs in patients with Gly719Xaa or Leu861Gln mutations. Moreover, in patients with Ser768Ile mutations, the response rate of osimertinib was better than the first-generation EGFR-TKIs. Although both osimertinib and some EGFR-TKIs have shown relatively high efficacy in treating rare EGFR mutations, there are several other issues that should be taken into account when selecting a drug, i.e., CNS activity and toxicities. Recent data has shown that osimertinib is undoubtedly associated with a reduced risk of CNS progression. Consistent with a previous study,12 the adverse events of osimertinib in this study16 were mainly limited to grade 1–2, with acceptable safety. Additionally, the discontinuation and dose modification due to adverse events were uncommon. However, there were some accompanying limitations of this study16 that are worth mentioning: (i) Instead of whole-genome sequencing, the authors used a low sensitivity and small sequencing coverage method (PCR combined with direct sequencing) to detect EGFR mutations. Therefore, there are certain limitations in detecting EFGR mutations; (ii) in addition to patients receiving first-line osimertinib therapy, this study also included patients receiving second- and third-line osimertinib therapy. In my opinion, the authors should perform a separate analysis of the homogeneous treatment group in subsequent studies; (iii) the number of patients with each of the rare EGFR mutations in this study was small, so a larger number of patients must be recruited in additional future studies to validate these findings. The study of Cho et al.16 is currently the first prospective study investigating the efficacy of osimertinib in NSCLC patients harboring rare EGFR mutations; reflecting the high response rate, long duration of response, and controllable toxicity of osimertinib. Although it had some accompanying shortcomings, the findings still evinced that osimertinib can be considered as a new therapeutic option for treating NSCLC patients with rare EGFR mutations. The authors declare there are no competing interests." @default.
• W3004245816 created "2020-02-07" @default.
• W3004245816 creator A5002310922 @default.
• W3004245816 creator A5020129921 @default.
• W3004245816 creator A5051117286 @default.
• W3004245816 date "2020-01-28" @default.
• W3004245816 modified "2023-10-06" @default.
• W3004245816 title "New data highlighting the efficacy and safety outcomes of third‐generation EGFR‐TKI in NSCLC patients with rare EGFR mutations" @default.
• W3004245816 cites W1999074023 @default.
• W3004245816 cites W2113521542 @default.
• W3004245816 cites W2139804581 @default.
• W3004245816 cites W2160982674 @default.
• W3004245816 cites W2166084034 @default.
• W3004245816 cites W2339311613 @default.
• W3004245816 cites W2591118779 @default.
• W3004245816 cites W2760639821 @default.
• W3004245816 cites W2770828094 @default.
• W3004245816 cites W2806156071 @default.
• W3004245816 cites W2883505792 @default.
• W3004245816 cites W2887416920 @default.
• W3004245816 cites W2889646458 @default.
• W3004245816 cites W2943606118 @default.
• W3004245816 cites W2985704506 @default.
• W3004245816 cites W2995864319 @default.
• W3004245816 cites W4234236664 @default.
• W3004245816 doi "https://doi.org/10.1111/1759-7714.13334" @default.
• W3004245816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7049494" @default.
• W3004245816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31989783" @default.
• W3004245816 hasPublicationYear "2020" @default.
• W3004245816 type Work @default.
• W3004245816 sameAs 3004245816 @default.
• W3004245816 citedByCount "1" @default.
• W3004245816 countsByYear W30042458162023 @default.
• W3004245816 crossrefType "journal-article" @default.
• W3004245816 hasAuthorship W3004245816A5002310922 @default.
• W3004245816 hasAuthorship W3004245816A5020129921 @default.
• W3004245816 hasAuthorship W3004245816A5051117286 @default.
• W3004245816 hasBestOaLocation W30042458161 @default.
• W3004245816 hasConcept C121608353 @default.
• W3004245816 hasConcept C126322002 @default.
• W3004245816 hasConcept C143998085 @default.
• W3004245816 hasConcept C2777506169 @default.
• W3004245816 hasConcept C2779438470 @default.
• W3004245816 hasConcept C71924100 @default.
• W3004245816 hasConceptScore W3004245816C121608353 @default.
• W3004245816 hasConceptScore W3004245816C126322002 @default.
• W3004245816 hasConceptScore W3004245816C143998085 @default.
• W3004245816 hasConceptScore W3004245816C2777506169 @default.
• W3004245816 hasConceptScore W3004245816C2779438470 @default.
• W3004245816 hasConceptScore W3004245816C71924100 @default.
• W3004245816 hasIssue "3" @default.
• W3004245816 hasLocation W30042458161 @default.
• W3004245816 hasLocation W30042458162 @default.
• W3004245816 hasLocation W30042458163 @default.
• W3004245816 hasLocation W30042458164 @default.
• W3004245816 hasOpenAccess W3004245816 @default.
• W3004245816 hasPrimaryLocation W30042458161 @default.
• W3004245816 hasRelatedWork W2025083754 @default.
• W3004245816 hasRelatedWork W2037032877 @default.
• W3004245816 hasRelatedWork W2184487997 @default.
• W3004245816 hasRelatedWork W2277378171 @default.
• W3004245816 hasRelatedWork W2325624862 @default.
• W3004245816 hasRelatedWork W2329432871 @default.
• W3004245816 hasRelatedWork W2386230446 @default.
• W3004245816 hasRelatedWork W2803053501 @default.
• W3004245816 hasRelatedWork W3138227302 @default.
• W3004245816 hasRelatedWork W4234363737 @default.
• W3004245816 hasVolume "11" @default.
• W3004245816 isParatext "false" @default.
• W3004245816 isRetracted "false" @default.
• W3004245816 magId "3004245816" @default.
• W3004245816 workType "article" @default.